Published on October 11, 2024 at 07:29. / Modified on October 11, 2024 at 07:33.
Anti-obesity drugs continue to conquer the world. Since Tuesday, Wegovy from Danish company Novo Nordisk has been available for sale in France. Authorized since 2022 at the European Union level, it had until then remained reserved for a limited number of patients with priority access. The treatment, which remains subject to a medical prescription, will not however be reimbursed by Social Security. Quoted by several French media, the president of the Federation of Pharmaceutical Unions of France estimates that a box of four injections (i.e. one month of treatment) will be sold between 270 and 330 euros, for a purchase price by pharmacists of between 208 and 220 euros.
Access to these anti-obesity treatments which are currently making the fortune of Novo Nordisk and its American competitor Eli Lilly, is therefore not within the reach of all budgets. In the United States, the cost of semaglutide (from Novo Nordisk) and tirzepatide (from Eli Lilly) is currently the subject of political debate. The use of these GLP-1 analogs – a new class of treatments originally developed to treat diabetes that have proven effective in weight loss – is limited under the Medicare program. The law only authorizes their reimbursement for prescriptions concerning diabetes or certain heart conditions. Since March, Novo Nordisk’s Wegovy has been supported for obese people with heart risk, but still not for weight management alone.
Explore and support “Le Temps” with a one-year subscription at -50%
Flash Sale: -50% on digital subscriptions!
A year of reliable information at half price. Offer valid until October 15, 2024.
I subscribe
Good reasons to subscribe to Le Temps:
- Unlimited access to all content available on the website.
- Unlimited access to all content available on the mobile application
- Sharing plan of 5 articles per month
- Consultation of the digital version of the newspaper from 10 p.m. the day before
- Access to supplements and T, the Temps magazine, in e-paper format
- Access to a set of exclusive benefits reserved for subscribers
Already a subscriber?
Log in
